Aryx Therapeutics Inc.

Dr. Goddard has served as the chairman of our board of directors since August 2003 and was appointed our chief executive officer in April 2005. From March 2000 and August 2005, Dr. Goddard served as chairman and part-time executive of several companies including A.P. Pharma, Inc., a pharmaceutical company, and XenoPort, Inc., a biopharmaceutical company. From October 1998 until March 2000, he was chief executive officer of Elan Pharmaceuticals, Inc., the largest division of Elan Corporation plc, a biotechnology company. He was chief executive officer of Neurex Corporation, a biotechnology company, from February 1991 until October 1998 when the company was acquired by Elan Corporation plc. Prior to 1991, Dr. Goddard held various senior management positions at SmithKline Beecham plc, a pharmaceutical company, including senior vice president strategic marketing and senior vice president Far East region. He obtained his doctorate degree from St. Mary's Hospital, London, in the area of etiology and pathophysiology of colon cancer. Dr. Goddard remains on the board of directors of A.P. Pharma, Inc., Adolor Corporation, a biopharmaceutical company, and Onyx Pharmaceuticals, Inc., a biopharmaceutical company.

Dr. Milner is our co-founder and has served as president, research and development, since April 2005 and a member of our board of directors since February 1997. Dr. Milner is a board certified physician and cardiologist, and serves as voluntary clinical faculty at Stanford Veterans' Hospital. In June 1992, Dr. Milner co-founded CV Therapeutics, Inc., a biopharmaceuticals company. Prior to CV Therapeutics, Inc., Dr. Milner was an assistant professor of medicine at Washington University in St. Louis, Missouri. Dr. Milner has numerous patents in his name and is the author of several scientific articles published in peer-reviewed journals. Dr. Milner attended the University of Liverpool, England where he received a bachelor of sciences degree with honors in biochemistry and a degree in medicine. He completed his postgraduate training in medicine at Johns Hopkins Medical School, cardiology and pharmacology at University of Virginia and molecular biology at Washington University in St. Louis. Dr. Milner is a Fellow of the American College of Cardiology, serves on the board of directors of California Healthcare Institute and the Scientific Advisory Board of Novartis Institute of Biomedical Research in Cambridge, Massachusetts.

Dr. Canafax has served as our vice president and chief development officer since February 2007. Dr. Canafax has overall responsibility for the development of our pipeline of products from preclinical development through clinical trials. From July 2002 to February 2007, Dr. Canafax served as vice president of clinical development at XenoPort, Inc. From June 2001 to July 2002, Dr. Canafax acted as director and medical monitor at MedImmune, Inc., a pharmaceutical company. Dr. Canafax received his B. Pharm. degree from Washington State University and his Pharm.D. degree from the University of Kentucky.

Mr. Varian has served as our chief operating officer since December 2003 and as our chief financial officer since April 2006. He was formerly chief financial officer of Genset S.A., a biotechnology company. He also participated as a key member of the negotiating team in the sale of the company to Serono of Switzerland. From October 1998 to April 2000, Mr. Varian served as senior vice president, finance and administration of Elan Pharmaceuticals, Inc. He was chief financial officer of Neurex Corporation from June 1997 until October 1998 when the company was acquired by Elan Corporation plc. Mr. Varian serves on the board of directors of biotechnology companies Nventa Biopharmaceuticals Corporation and Xoma. He is a founding member of the Bay Area Bioscience Center and a former chairman of the Association of Bioscience Financial Officers International Conference. Mr. Varian received a B.B.A. degree from Western Michigan University.

Dr. Druzgala is our co-founder and has served as senior vice president and chief scientific officer since June 2008, and prior to that as vice president and chief scientific officer since our inception. Dr. Druzgala is responsible for all research related activities of our company. Prior to the founding of ARYx, Dr. Druzgala also co-founded Advanced Therapies, Inc., a biopharmaceutical company, in October 1994. Earlier in his career, Dr. Druzgala served as group leader at Xenon Vision, where the retrometabolic drug design concept was applied to four drugs for ocular delivery. One of these drugs, loteprednol etabonate (Alrex® or Lotemax®), is now marketed by Bausch & Lomb, Inc., an eye care company. Dr. Druzgala was a Ph.D. chemist at Pharmatec working on brain-delivery systems for antivirals and estrogens. Dr. Druzgala received a Pharm.D degree from the University of Montpellier, France, and then earned his dipl™me d'études approfondies degree at the European Institute of Industrial Pharmaceutical Sciences in Montpellier, France. Dr. Druzgala later graduated from the University of Florida with a doctorate in medicinal chemistry. He completed his post doctorate work at the Center for Drug Design and Discovery at the University of Florida where he first experimented with various drug discovery programs utilizing retrometabolic techniques.

Mr. Nagler has served as our vice president, corporate affairs, and secretary since July 2003. From June 1995 to September 2002, Mr. Nagler served at Genentech, Inc., a biotechnology company, including as its vice president of human resources and its senior director of government affairs. Prior to joining Genentech, Mr. Nagler co-founded JLA Associates in Sacramento, a legislative consulting and association management company that he later sold to Nossaman Guthner Knox & Elliott LLP, a law firm. Mr. Nagler received a bachelor of arts degree in public policy and philosophy from the University of California, Berkeley. Mr. Nagler is a member of the board of directors of U.C. Davis CONNECT, a program designed to foster the success of new business ventures in the Sacramento region.

Dr. Ekman has served as a member of our board of directors since November 2003. He recently served as executive vice president and president of global research and development of Elan Pharmaceuticals for seven years. Prior to joining Elan, Dr. Ekman served as executive vice president, R&D, at Schwarz Pharma AG, a pharmaceutical company. Dr. Ekman has also served in a variety of senior scientific and clinical roles at Pharmacia Corp., which was acquired by Pfizer, Inc., a pharmaceutical company, for 14 years. Dr. Ekman is a board certified surgeon with a Ph.D. in experimental biology and has held several clinical and academic positions in both the United States and Europe. He obtained his doctorate degree and doctorate of medicine degree from the University of Gothenburg, Sweden. Dr. Ekman also serves on the board of directors at Elan Pharmaceuticals, Amarin Corp., InterMune, Inc., and Cebix, Inc.

Mr. Simon has served as a member of our board of directors since June 2002. In February 2005, Mr. Simon co-founded Clarus Ventures, LLC, a venture capital firm focused on life sciences companies. Mr. Simon has been a general partner of MPM BioVentures III, a healthcare venture capital fund, since October 2001. From April 2000 to July 2001, Mr. Simon was chief executive officer and founder of Collabra Pharma, Inc., a pharmaceutical company. Mr. Simon served in various management positions at Genentech, Inc., including its vice president of business and corporate development. Mr. Simon is currently on the board of directors of Sientra, Inc., and several pharmaceutical companies: Barrier Therapeutics, Inc., Neosil, Inc., QuatRx Pharmaceuticals Company, Pearl Therapeutics, Inc., Poniard Pharmaceuticals, Inc., and Verus Pharmaceuticals, Inc. He is also on the advisory council of the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California, San Francisco. Mr. Simon received a bachelor of sciences degree in microbiology from the University of Maryland and a masters in business administration in marketing from Loyola College.

Paul Sekhri is the President and Chief Executive Officer of Cerimon Pharmaceuticals. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc., a NASDAQ-listed oncology company based in Cambridge, MA. In 2002 Mr. Sekhri joined the Sprout Group, the venture affiliate of Credit Suisse First Boston in New York, where he was a Partner for healthcare technology investments. Prior to joining Sprout, Mr. Sekhri spent four years at Novartis, most recently as Senior Vice President and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. At Novartis, he was responsible for the creation of Novartis Pharmaceuticals' Disease Area Strategy, as well as establishing a dedicated function focused on the identification and evaluation of new opportunities for the company. Prior to this, Mr. Sekhri set up a new department, Early Commercial Development, in order to ensure the differential competitive advantage of Novartis' pipeline. Mr. Sekhri completed graduate work in neuroscience at the University of Maryland School of Medicine where he also received his BS in Zoology. Mr. Sekhri is currently a member of the Board of Directors for Biodel Inc. based in Danbury, Connecticut and ARYx Therapeutics, a San Francisco based pharmaceutical company where he also serves as chairman of the compensation committee. Mr. Sekhri also serves on the Board of Directors of the Irvington Institute for Immunological Research, a non-profit world leader in the funding of basic research in immunology. Mr. Sekhri is a Venture Partner with MPM Capital, one of the largest Venture Capital firms devoted to the life sciences.

Rob Adelman, M.D., Private Equity Partner. Dr. Adelman joined OrbiMed in 2002 to focus on private equity investments and structured transactions of small-capitalization public equity companies. Prior to joining OrbiMed, Dr. Adelman was Vice President of Business Development at NeoGenesis Pharmaceuticals. Prior to his tenure with NeoGenesis, he was a founder of Veritas Medicine. He was also a co-founder of Operon Technology, one of the largest commercial producers of synthetic DNA in the world. He trained as an orthopedic surgeon at the Hospital for Special Surgery at Cornell University. As a practicing orthopedic surgeon, he was involved with major implant manufacturers on hip and knee replacement design. Dr. Adelman received his B.A. with the highest honors from the University of California, Berkeley and his M.D. from Yale University School of Medicine. Dr. Adelman serves on the Boards of Volcano Corporation, CryoCor Inc, Sientra Inc., Aryx Inc, Innovative Spinal Technologies Inc, and Cerimon Pharmaceuticals.